Navigation Links
Abbott to Preview New CELL-DYN(R) Emerald(TM) Hematology Instrument
Date:7/28/2008

CELL-DYN Emerald Designed to Deliver Quick, Reliable Results for Small to

Mid-Sized Laboratories

WASHINGTON, July 28 /PRNewswire-FirstCall/ -- Abbott (NYSE: ABT) will preview an upcoming addition to the CELL-DYN(R) family of hematology instruments, the Emerald(TM), at the American Association of Clinical Chemistry (AACC) Annual Meeting this week. The Emerald is designed to be a valuable tool for performing complete blood counts (CBCs) -- a test frequently ordered by doctors to assess a patient's overall health and to screen for a variety of disorders such as anemia and infection. The Emerald has the ability to complete CBC results in 60 seconds and report results in easy-to-read histograms representing white blood cells, red blood cells and platelets.

Expected to be available in the United States by the end of the year, subject to regulatory clearance, the Emerald will expand Abbott's hematology platform by offering a premium, robust low-volume solution for small to mid-sized clinical laboratories. Enhanced technology combined with intuitive software and onboard reagents enable the Emerald to offer reliable performance while promoting faster and simpler data entry.

As low to medium-volume hospital laboratories and clinics continue to seek greater efficiency under tight space limitations, the Emerald is expected to deliver reliable, productivity-enhancing performance in a small footprint.

The AACC Annual Meeting is a global meeting that attracts nearly 20,000 attendees from more than 100 countries. The Emerald is on display in Abbott's AACC exhibit booth (No. 1507).

About CELL-DYN

Abbott's CELL-DYN family of hematology instruments is well known for its efficiency and ability to provide fast access to patient results. Instruments range from larger analyzers that process a high number of patient samples to smaller instruments designed for medium and small-volume facilities. Besides supplying standard CBC results, some instruments have additional features to aid in the evaluation of more complex disease states or infections including cancer, HIV and a variety of anemias.

About Abbott's Diagnostics Businesses

Abbott is a global leader in in vitro diagnostics and offers a broad range of innovative instrument systems and tests for hospitals, reference labs, molecular labs, blood banks, physician offices and clinics. With more than 65,000 customers in more than 100 countries, Abbott's diagnostic products offer customers automation, convenience, bedside testing, cost effectiveness and flexibility. Abbott has helped transform the practice of medical diagnosis from an art to a science through the company's commitment to improving patient care and lowering costs. Abbott's history is filled with examples of first-of-a-kind diagnostic products and significant technological and research advancements.

About Abbott

Abbott is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics. The company employs more than 68,000 people and markets its products in more than 130 countries.

Abbott's news releases and other information are available on the company's Web site at http://www.abbott.com.


'/>"/>
SOURCE Abbott
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Abbott to Present at Bear Stearns Healthcare Conference
2. The National Center for Missing & Exploited Children, Wal-Mart, and Abbott Host Child Safety Events
3. Dow Jones Sustainability Index Again Recognizes Abbott for Continued Leadership in Business, Environmental and Social Performance
4. Abbott Declares 335th Consecutive Quarterly Dividend
5. Abbott Again Honored as Top Company for Working Moms
6. Abbotts HUMIRA(R) (adalimumab) Honored With Prestigious Galen Prize for Innovation in Patient Care
7. Abbott Hosts Conference Call for Third-Quarter Earnings
8. Abbott Broadens Use of i-STAT Handheld Blood Analyzer with CLIA Waiver Granted by FDA for CHEM8+ Test Cartridge
9. Abbott Named One of the Best Companies for Hispanics by Hispanic Business Magazine
10. Abbott Again Honored as a Leader in Diversity
11. Abbott Researchers Target Neuronal Nicotinic Receptors for Treatment of Pain and Cognition
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... ... March 28, 2017 , ... AutismOne announced the ... Association of Integrative Medicine and available for application on Saturday, May 27, 2017, ... Conference in Colorado Springs. , Ed Arranga, president of AutismOne, stated: "Many of ...
(Date:3/28/2017)... (PRWEB) , ... March 28, 2017 , ... ... Association’s Tri-State Camp Conference in Atlantic City March 13-16, was a busy spot ... team of professional staff discussed strategies for preventing outbreaks among camp communities during ...
(Date:3/28/2017)... ... ... Oily skin is a common and unwelcomed occurrence in people of all ages, genders and ... to the discussion of dealing with excess skin oil. “Oily skin is a challenge to ... can help remove the oily shine while keeping the skin fresh and clean,” says Dr. ...
(Date:3/28/2017)... ... 28, 2017 , ... “A Prophets Bones”: a thrilling adventure that reveals the mystery of Kevin’s ... things that his parents and teachers had asked of him that he had neglected to ... to defy the Almighty Creator. There were some who would have felt themselves to be ...
(Date:3/27/2017)... ... March 27, 2017 , ... The respected ... who want straight teeth without the extensive time commitment and aesthetic disadvantages of ... acquiring a referral. A custom-designed series of virtually invisible aligners are created for ...
Breaking Medicine News(10 mins):
(Date:3/27/2017)... Israel , March 27, 2017 ... oncology and immunology, announced today that AGI-134, an immunotherapy for ... acquisition of Agalimmune Ltd., will be featured at the upcoming ... in Washington, DC to be held ... ...
(Date:3/27/2017)... , March 27, 2017  BERG, a ... data-driven, biological research approach, today announced that ... the discovery of new data using a ... brown fat metabolism. Joslin Diabetes Center led ... Biology® platform for analysis of samples.  The ...
(Date:3/27/2017)... BOSTON , March 27, 2017  Allergan ... and Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a biopharmaceutical ... innovative therapies based upon tetracycline chemistry, announced that ... the treatment of moderate to severe acne met ... a once-daily, oral, narrow spectrum tetracycline-derived antibiotic with ...
Breaking Medicine Technology: